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Abstract
Background: The emergence of influenza strains that are resistant to commonly used antivirals
has highlighted the need to develop new compounds that target viral gene products or host
mechanisms that are essential for effective virus replication. Existing assays to identify potential
antiviral compounds often use high throughput screening assays that target specific viral replication
steps. To broaden the search for antivirals, cell-based replication assays can be performed, but
these are often labor intensive and have limited throughput.
Results: We have adapted a traditional virus neutralization assay to develop a practical, cell-based,
high throughput screening assay. This assay uses viral neuraminidase (NA) as a read-out to quantify
influenza replication, thereby offering an assay that is both rapid and sensitive. In addition to
identification of inhibitors that target either viral or host factors, the assay allows simultaneous
evaluation of drug toxicity. Antiviral activity was demonstrated for a number of known influenza
inhibitors including amantadine that targets the M2 ion channel, zanamivir that targets NA, ribavirin
that targets IMP dehydrogenase, and bis-indolyl maleimide that targets protein kinase A/C.
Amantadine-resistant strains were identified by comparing IC50 with that of the wild-type virus.
Conclusion: Antivirals with specificity for a broad range of targets are easily identified in an
accelerated viral inhibition assay that uses NA as a read-out of replication. This assay is suitable for
high throughput screening to identify potential antivirals or can be used to identify drug-resistant
influenza strains.
Background
Outbreaks of influenza account for much morbidity dur-
ing winter months, and result in tens of thousands of
deaths each year. The elderly and very young are particu-
larly susceptible to more severe respiratory disease and
death due to influenza. These individuals can be vacci-
nated but because the young are immunologically naïve,
and the elderly are immunosenescent, vaccine prepara-
tions lack immunogenicity in these population groups [1-
3]. Antivirals would clearly benefit these individuals and
in addition would be of great value to the global popula-
tion when no suitable vaccine is available to prevent infec-
tion [4]. This is likely the case when there is antigenic shift
and a new virus strain emerges that could result in a
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world-wide pandemic. Pandemics that occurred in 1918,
1957 and 1968 were each the result of the transmission of
influenza with a unique HA subtype, with the introduc-
tion of H1, H2 and H3 hemagglutinin (HA) gene seg-
ments from an avian virus source [5].
The avian H5N1 virus that is currently a pandemic threat
has resulted in hundreds of human infections, with
approximately 60% mortality rate. If such a strain
becomes easily transmissible amongst people, there will
be extensive death and disease unless a prophylactic vac-
cine is used or antivirals are administered. The only H5N1
vaccine licensed for emergency use in the United States
contains inactivated A/Vietnam/1203/2004. There is no
assurance that this vaccine will antigenically match the
pandemic H5N1 strain, and so vaccine efficacy cannot be
predicted. There is therefore a great need to stockpile effec-
tive antiviral drugs. Unfortunately, there are only two
classes of antivirals that can be used to treat influenza;
adamantanes that inhibit virus replication by blocking the
influenza A M2 ion channel and neuraminidase (NA)
inhibitors. Of these, the adamantanes are no longer effec-
tive against many recent influenza A virus strains [6,7] and
most H5N1 strains are resistant to this class of drug [8].
Decreased sensitivity to the second class of antivirals that
inhibit NA activity has been noted [9], and H1N1 viruses
that are resistant to one of the two licensed NA inhibitors,
oseltamivir, are prevalent in Europe [10].
In addition to problems associated with emergence of
drug-resistant virus strains, each drug class has potential
side effects. While the NA inhibitors were generally
thought to have fewer toxic effects than amantadine and
rimantadine, oseltamivir is no longer prescribed to chil-
dren in Japan because of an association with neuropsychi-
atric disorders that include suicidal behavior,
hallucinations and seizures [11]. Oseltamivir-induced
delirium has also been reported in a geriatric patient [12].
There is clearly a need for licensure of additional inhibi-
tors against influenza, particularly inhibitors to which
resistant virus strains are less likely to emerge.
To fill this need, several new candidate antiviral agents
have been identified [13]. In the process to select new can-
didates, methods targeted to a specific gene product or
particular virus replication steps are commonly used; for
example, viral RNA transcription [14]. However, assays
that allow for identification of inhibitors with a broad
range of targets increase the likelihood of obtaining a
product that is effective. Unfortunately these latter viral
inhibition assays are usually not suited to high through-
put screening (HTS). In this report we describe modifica-
tions of the standard virus neutralization assay that
facilitates its use in HTS. The key element to this assay is
the use of viral NA as a means to quantify virus replication
early after infection. This affords higher throughput with
excellent signal/noise ratios, providing excellent assay
sensitivity. In addition to presenting these properties, we
use known influenza virus inhibitors to demonstrate the
broad spectrum of antivirals detected by this assay.
Results and discussion
NA activity is a measure of influenza virus concentration
NA activity is required for release of newly formed virus
particles from the infected cells [15] and consequently it
is expected that all natural isolates of influenza A and B
viruses have this enzyme activity. Approximately 50–100
NA molecules are incorporated into each virion and its
activity has previously been used to quantify virus [16].
For the purpose of developing a high throughput screen-
ing assay, we needed to show that NA activity is readily
measured in virus preparations after 1 hr incubation of
virus with a fluorescent substrate, methyl-umbelliferyl-N-
acetyl neuraminic acid (MU-NANA), and the read-out is
proportional to the amount of virus present. The use of
small chromagenic NA substrates has been appreciated for
some time [17,18] and the use of MU-NANA substrate
was first described in 1979 [19]. MU-NANA has subse-
quently been used to evaluate resistance of influenza to
NA inhibitors [20].
We incubated different dilutions of virus with MU-NANA
for 1 hour and measured relative fluorescence units (RFU)
after addition of stop solution. The read-out (RFU) was
directly proportional to the amount of virus added to each
assay well (Figure 1). This confirmed the suitability of NA
activity as a practical end-point index for development of
a high throughput assay with rapid read-out for inhibition
of virus replication. This "accelerated" virus inhibition
NA activity can be used to quantify virus Figure 1
NA activity can be used to quantify virus. A/Wisconsin/
67/2005 was serially diluted in PBS and 50 μl incubated with 
an equal volume of 20 μM MU-NANA for 1 hour at 37°C. 
Stop solution was added before reading fluorescence. The 
signal to background ratio at each concentration is shown. 
Under these conditions enzyme activity reaches a plateau 
with > 5 × 105 TCID50 due to limiting substrate.
TCID50 x 103/well
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(AVI) assay with NA as read-out was therefore called the
"AVINA" assay.
NA activity reflects replication of influenza in cells 
inoculated with a low virus dose
In the AVINA assay, a monolayer of cells is infected with
virus in the presence or absence of inhibitor. MU-NANA is
then added to the plate, or to supernatants from the plate,
and the product of NA cleavage measured 1 hr later. This
allows results to be obtained quickly and has the advan-
tage that residual input virus is not detected since the
inoculum dose (multiplicity of infection (MOI) of 0.01 to
0.02) is not detected under these conditions.
We established the assay conditions by comparing cell
types, number of cells, medium, MOI, time of incubation
with virus, time and temperature of incubation with NA
substrate, and substrate concentration. Conditions that
gave the greatest Z' scores (the confidence of identifying
an inhibitor [21]), signal to background ratio and sensi-
tivity were selected. A kinetic study that measured NA
activity in supernatants collected at different time points
after infection showed that while fairly good signals were
obtained 16 hr post-infection, signal strength was
increased and variability decreased when supernatants
were harvested 20–22 hr post-infection (data not shown).
Under these conditions, reproducible results were
obtained within 24 hr of assay set-up.
The primary inhibitors used to determine assay condi-
tions suitable to identify antivirals were amantadine, an
inhibitor of M2 ion channel activity [22] and zanamivir,
an inhibitor of NA activity [23]. We showed inhibition by
zanamivir and amantadine when cells were infected with
influenza at a MOI between 0.01 and 0.1 for 16–24 hr.
After incubation with virus, consistent results were
obtained when the substrate was added to either the orig-
inal MDCK-containing wells or the supernatants from
infected cells. Figure. 2 shows data from an experiment
that titrated zanamivir against A/Memphis/14/98. As
expected, NA activity in cells with residual supernatant
was greater than a small volume of supernatant alone (in
the absence of inhibitor, relative fluorescence units (RFU)
was 300,000 and 250,000 respectively). This difference
reflects the additional activity of NA that is expressed on
the surface of infected cells.
We hypothesized that measuring NA activity in superna-
tants would provide a more sensitive assay than quantify-
ing NA activity in both cells and supernatants. When
calculated from data shown in Figure 2, the 50% effective
inhibition concentration (IC50) of zanamivir against A/
Memphis/14/98 was 4.2 nM and 2.8 nM for assays that
added substrate to the cell culture wells and cell superna-
tants, respectively. A similar increase in assay sensitivity
was observed when IC50 of amantadine was calculated
from the amount of NA activity in the supernatant. For A/
Memphis/14/98, an IC50  > 33 μM was calculated for
amantadine when NA activity of the total culture was
quantified, while an IC50 of 1.2 μM was calculated when
the amount of NA in the supernatant was measured. These
differences support our hypothesis that measurement of
NA activity in cell supernatants results in a more sensitive
assay.
The AVINA assay can be used with a broad spectrum of 
viruses and antivirals
Since NA is the read-out, viruses that are deficient in NA
activity are not suitable for this assay. However, such NA-
deficient viruses are not naturally selected and require
addition of exogenous NA for in vitro growth. We success-
fully used the AVINA assay with a number of influenza A
and B viruses. This included influenza A subtype H1N1
(A/PR/8/34 and A/New Caledonia/20/99), subtype H3N2
(A/Wuhan/359/95, A/Memphis/14/98 and A/Wisconsin/
67/2005) and influenza B (B/Jiangsu/10/2003 and B/
Malaysia/2506/2004).
The AVINA assay was largely established using A/Mem-
phis/14/98 (H3N2) since it is sensitive to both amanta-
dine and zanamivir, providing positive controls to
optimize assay sensitivity. To evaluate the specificity of
NA activity in cell culture wells and in the supernatants of  cells infected 20 hr earlier in the presence of different  amounts of zanamivir Figure 2
NA activity in cell culture wells and in the superna-
tants of cells infected 20 hr earlier in the presence of 
different amounts of zanamivir. In this experiment, 
MDCK cells were infected with 400 TCID50 A/Memphis/14/
98 (MOI = 0.01). The inoculated amount of virus is not suffi-
cient to measure NA activity at the selected conditions.
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the assay, we determined the IC50 of zanamivir and aman-
tadine against a number of different viruses. All viruses
tested were sensitive to zanamivir; the IC50 of A/PR/8/34
(H1N1) was 3.6 nM, A/New Caledonia/20/99 (H1N1)
was 3.0 nM, A/Memphis/14/98 (H3N2) was 2.8 nM. B/
Jiangsu/10/2003 was less sensitive to inhibition by zan-
amivir, with an IC50 of 26.3 nM. Reduced sensitivity to
zanamivir of Type B viruses in assays that measure inhibi-
tion of NA activity directly has been reported [20,24]. In
these latter studies, the absolute IC50 values are similar but
not identical to what we report, probably reflecting differ-
ences in the assays used: IC50 determined by inhibition of
NA activity of whole virus does not measure the 'effective'
inhibition of virus replication as is the case for our AVINA
assay.
The AVINA assay correctly identifies virus sensitivity to
amantadine (Figure 3). A/Memphis/14/98, showed good
inhibition of replication in the presence of amantadine
(IC50 is 1.2 μM). A/PR/8/34, a virus with known resistance
to amantadine, was not inhibited by this drug (IC50 > 100
μM). As expected, influenza B viruses were resistant to
amantadine.
To evaluate the breadth of antiviral targets that can be
detected in the AVINA assay, we determined the IC50 for
ribavirin, a broad spectrum antiviral that blocks viral rep-
lication [25], largely due to inhibition of IMP dehydroge-
nase [26], and bis-indolyl maleimide (BIM), an inhibitor
of protein kinase A/C activity that is required for virus
assembly [27]. Ribavirin is a nucleoside antimetabolite
that protects mice from both lethal doses of influenza A
and B viruses [25,28] but since results of clinical trials
were mixed, this drug was not approved for use an anti-
influenza agent in the USA [29]. In addition, ribavirin has
severe side-effects: hemolytic anemia is observed, and it is
a teratogen in some species. Oral ribavirin is however,
available for treating influenza in Mexico (Vilona, ICN
pharmaceuticals). In the AVINA assay, the IC50 of ribavirin
for A/Memphis/14/98 was 10.8 μM (Figure 4).
The protein kinases play a role in cellular functions that
are required for successful influenza replication [30].
Inhibitors of protein kinase C such as BIM may prevent
activation of ERK signaling that is necessary for export of
the viral genome from the nucleus [27], or may have an
effect on M2 ion channel activity since inhibition of cellu-
lar cation channel activity has been reported for BIM [31].
The IC50 of BIM measured by titration of the drug with A/
Memphis/14/98 in the AVINA assay is 23 μM (Figure 5).
This is a fairly high concentration (compared with IC50 of
zanamivir and amantadine), raising concern that the
observed inhibition is a result of its impact on cell viabil-
ity and not a direct effect on virus replication. In prelimi-
nary experiments (data not shown) we demonstrated that
cell viability in the AVINA assay can easily be determined
by measuring ATP concentration in the culture (ATPlite
assay, Perkin Elmer) after removal of a small volume of
supernatant to assay NA activity. The cytotoxicity of each
drug can therefore be evaluated in the same plate used to
determine virus replication. There are some exceptions in
which the stress response to a particular drug induces
greater synthesis of ATP, resulting in data that is difficult
to interpret. The relative light units (RLU) that reflect ATP
levels at each BIM concentration are shown together with
NA activity in Figure 5. BIM was not toxic to the cells at 23
μM but did show significant toxicity at 83 μM. While our
Titration of amantadine against influenza A and B viruses in  the AVINA assay Figure 3
Titration of amantadine against influenza A and B 
viruses in the AVINA assay. Cells were infected with A/
PR/8/34, A/Memphis/14/98 and B/Jiangsu/10/2003 at 0.01 
MOI in the presence of serial dilutions of amantadine. The 
next day, NA activity was measured in the supernatant and 
IC50 calculated by GraphPad Prism software.
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Titration of ribavirin against A/Memphis/14/98 in the AVINA  assay Figure 4
Titration of ribavirin against A/Memphis/14/98 in the 
AVINA assay. Cells were infected with 0.01 MOI A/Mem-
phis/14/98 in the presence of serial dilutions of ribavirin. The 
next day, NA activity was measured in the supernatant and 
IC50 calculated by GraphPad Prism software.
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results show specific inhibition of influenza virus replica-
tion by this protein kinase inhibitor, BIM is toxic to cells
at doses that would need to be administered therapeuti-
cally, making it a poor antiviral candidate.
The AVINA assay can be used in a high throughput format
Final assay conditions were used in a blind screen of an
ion channel inhibitor panel. The assay includes negative
(quadruplicate wells that contained no inhibitor), and
positive control wells (duplicate wells with 330 nM zan-
amivir or 33 μM amantadine), as shown in Figure 6. The
results identified amantadine (Figure 6, well A5) and an
amantadine derivative (Figure 6, well D6) as inhibitors of
A/Memphis/14/98.
The AVINA assay can be used to identify drug-resistant 
viruses
Culture of A/Memphis/14/98 in flasks of MDCK cells with
33 μM amantadine resulted in observable CPE after 2
days. Virus in this culture supernatant was passaged seri-
ally in the presence of amantadine and then the resultant
supernatant was used to generate a virus stock (in the
absence of inhibitor). After determining the TCID50 of
each virus stock, an equivalent MOI of each virus prepara-
tion was used to infect MDCK cells in an AVINA assay that
measured sensitivity to amantadine. Virus generated after
a single passage in the presence of amantadine was
slightly less sensitive to amantadine than the original
stock; a 2nd passage resulted in greater resistance and by
the 4th passage was completely resistant to amantadine
(Figure 7). Our results demonstrate that even within a
pool of viruses, the AVINA assay is capable of evaluating
differences in sensitivity to viral inhibitors.
Conclusion
In this report we describe the development of the AVINA
assay, a high throughput assay that measures NA activity
as a read-out for virus replication. The advantages of this
assay are its ease of execution, reproducibility, and sensi-
tivity to antivirals that target both early and late stages of
replication with specificity for either viral or cellular tar-
gets. This assay can be applied to high throughput screen-
ing of chemical libraries to identify antivirals or can be
used to determine IC50 and identify antiviral resistant
virus strains.
Methods
Virus preparation and titration
Standard methods were used to prepare virus stocks in
either MDCK cell cultures or embryonated chicken eggs
and titrate these stocks on MDCK cells [32]. The viruses
used were: tissue-culture adapted A/PR/8/34 (H1N1), A/
New Caledonia/20/99 (H1N1), A/Memphis/14/98
(H3N2), A/Wisconsin/67/2005 (H3N2), and B/Jiangsu/
10/2003. Briefly, a confluent layer of MDCK cells was
washed in serum-free medium and inoculated with virus
at a 0.001 MOI. After 3 days the preparation was centri-
fuged and the supernatant aliquoted and stored at -70°C.
Ten day old embryonated chicken eggs (CBT Farms, Ches-
tertown, MD) were inoculated with virus and incubated
for at least 48 hr. After overnight chilling at 4°C, the allan-
toic fluid was harvested, cellular debris pelleted and virus
aliquots stored at -70°C. The infectious titer of virus was
determined by ten-fold serial dilution and inoculation of
MDCK cells in quadruplicate wells of a 96-well plate.
Cytopathic effect indicated the presence of virus, with the
TCID50 end-point defined as the inverse of the dilution
that showed CPE in 50% of the wells.
Antivirals
Amantadine (Sigma Chemicals, St Louis MO) was dis-
solved in DMSO and then diluted to make a 2 mM stock
solution in PBS. Zanamivir (Relenza, Roche) 5 mg caplet
was dissolved in PBS to make a 2 μM solution. Stock solu-
tions (2 mM) of ribavirin (Sigma, St Louis, MO) and bis-
indolyl maleimide (BIM, Sigma) were prepared in PBS. All
stock solutions were aliquoted and stored at -20C.
Accelerated Viral Inhibition Assay
MDCK cells were washed in serum-free medium (EMEM
containing glutamine and penicillin and streptomycin)
and 50 μl aliquoted into flat-bottomed 96-well plates at 8
× 105/ml. In assays to define conditions, the cells were
allowed to adhere overnight before addition of 50 μl con-
trols (known antiviral agents or diluent (serum-free
medium)); 50 μl virus containing 0.02 MOI, followed by
Titration of bis-indolyl maleimide (BIM) against A/Memphis/ 14/98 in the AVINA assay Figure 5
Titration of bis-indolyl maleimide (BIM) against A/
Memphis/14/98 in the AVINA assay. Cells were infected 
with 0.01 MOI A/Memphis/14/98 in the presence of serial 
dilutions of BIM. The next day, NA activity was measured in 
the supernatant (shown as relative fluorescence units) and 
IC50 calculated by GraphPad Prism software. Cell viability was 
determined by ATPlite assay (shown as relative light units).
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50 μl EMEM containing 3% bovine serum albumin (BSA)
and TPCK-treated trypsin (5 μg/ml). However, assay
reproducibility and sensitivity was retained when antivi-
rals, virus, BSA and TPCK-trypsin were added simultane-
ously, and therefore the results shown in this report used
our standard conditions: antivirals (or dilutions of antivi-
rals) we made in 30 μl serum-free EMEM followed by the
addition of 90 μl virus diluted in EMEM containing BSA
(1%) and TPCK-treated trypsin (5 mg/ml). A portion (100
μl) of this mixture was added to wells containing MDCK
cells plated the previous day in serum-free medium. The
assay can also be performed without prior establishment
of a cell monolayer, with washed cells added directly to
the antiviral/virus mixture. Twenty hrs after incubation at
37°C in 5% CO2, 25 μl of the supernatant was harvested
for NA assay as described below. Viability of cells in the
culture plate was determined by ATPlite assay (Perk-
inElmer) following the manufacturer's instructions.
Neuraminidase assay
Cell supernatants (25 μl) were transferred to a black 96-
well plate and 75 μl of 20 μM MU-NANA added. After
incubation of the plate at 37°C for 1 hr, 100 μl stop solu-
tion (0.1 M glycine, pH 10.7–25% EtOH) was added to
each well and fluorescence read on a Victor V (Perkin
Elmer) with excitation and emission filters of 355 nm and
460 nm respectively.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software, with sigmoidal non-linear curves used to calcu-
late the IC50 of inhibitors.
List of abbreviations
AVINA: Accelerated Virus Inhibition assay, with NA as
read-out; BIM: bis-indolyl maleimide; BSA: bovine serum
albumin; CPE: cytopathic effect; ID50, 50% inhibition
dose; HA: hemagglutinin; HTS: high-throughput screen-
ing; MOI: multiplicity of infection; MU-NANA: methyl-
umbelliferyl-N-acetyl neuraminic acid; NA: neuramind-
ase; RFU: relative fluorescence units; RLU: relative light
units.
Declaration of competing interests
The authors declare that they have no competing interests.
Example of an HTS assay Figure 6
Example of an HTS assay. The plate map is shown in the upper panel, with wells set aside for background and virus con-
trols. Each plate also includes known inhibitors, zanamivir and amantadine, at concentrations known to inhibit virus replication. 
The lower panel shows the results of NA activity for an assay that evaluated the antiviral activity of a panel of ion channel inhib-
itors. Activity is represented by a range of color; blue representing low relative fluorescence units (RFU), that is, no or little 
NA activity, and red representing high RFU, that is, a high amount of NA activity.Virology Journal 2008, 5:109 http://www.virologyj.com/content/5/1/109
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Identification of amantadine-resistant virus prepara-
tions. A/Memphis/14/98 was cultured in the presence of 
amantadine for one passage (A/Mem/98 p1), two passages 
(A/Mem/98 p2), or 4 passages (A/Mem/98 p4) in tissue cul-
ture. The TCID50 of each virus passage was determined, and 
0.02 MOI added to serial dilutions of amantadine in the 
AVINA assay. The percent inhibition of virus replication is 
shown at each concentration of amantadine was calculated 
by: 100 × (average RFU at each amantadine concentration/
average RFU in the absence of amantadine).
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